Well-differentiated thyroid carcinoma has a favorable prognosis with a 5-year survival rate of
over 95%. However, the undifferentiated or anaplastic type accounting for< 0.2%, usually in …

Background Anaplastic thyroid carcinoma (ATC) is a notoriously aggressive malignancy
associated with a highly lethal clinical course despite therapeutic intervention. Our present …

Introduction Although anaplastic thyroid carcinoma (ATC) is rare, it is one of the most
aggressive human cancers. The optimal multimodal therapy policy of ATC is still debated …

Anaplastic thyroid cancer (ATC) is a rare tumour but also one of the most lethal
malignancies. Therapeutic modalities have usually been limited, but clinical trials with new …

Background: Anaplastic thyroid carcinoma (ATC) is a malignancy with one of the highest
fatality rates. Here we report a retrospective study of the treatment and other factors …

Background Anaplastic thyroid carcinoma (ATC), a highly aggressive malignancy, has a
poor prognosis, and the consensus on the most effective treatment is needed. Methods …

Opinion statement Anaplastic thyroid carcinoma (ATC) is a rare, highly aggressive tumor
characterized by rapid growth that causes death soon after diagnosis. Optimal treatment is …

Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally.
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …

Purpose Anaplastic thyroid cancer is known to have a poor prognosis due to its aggressive
and rapid metastasis with median survival of less than 6 months. Multimodal treatment …

Background Anaplastic thyroid carcinoma (ATC) accounts for only 1 to 2% of all thyroid
carcinomas, but it is one of the most lethal neoplasms in humans. To date, most findings …